41608-64-4

Basic information

• Product Name: Methyl 4-amino-3-methoxybenzoate
• Synonyms: Benzoic acid, 4-aMino-3-Methoxy-, Methyl ester;3-METHOXY-4-AMINOBENZOIC ACID METHYL ESTER;4-AMINO-3-METHOXYBENZOIC ACID ETHYL ESTER;METHYL 3-METHOXY-4-AMINOBENZOATE;METHYL 4-AMINO-3-METHOXYBENZENECARBOXYLATE;METHYL 4-AMINO-3-METHOXYBENZOATE;Methyl 4-amino-3-methoxybenzoate 98%;4-Amino-3-methoxy benzoic acid methyl ester
• CAS NO: 41608-64-4
• Molecular Formula: C₉H₁₁NO₃
• Molecular Weight: 181.19
• EINECS: 255-456-5
• Product Categories: Benzene derivatives;Aromatic Esters
• Mol File: 41608-64-4.mol

Chemical Properties

• Melting Point: 128-131°
• Boiling Point: 332 °C at 760 mmHg
• Flash Point: 175.4 °C
• Appearance: /
• Density: 1.179 g/cm³
• Vapor Pressure: 0.00015mmHg at 25°C
• Refractive Index: 1.55
• Storage Temp.: 2-8°C(protect from light)
• PKA: 2.41±0.10(Predicted)
• CAS DataBase Reference: Methyl 4-amino-3-methoxybenzoate(CAS DataBase Reference)
• NIST Chemistry Reference: Methyl 4-amino-3-methoxybenzoate(41608-64-4)
• EPA Substance Registry System: Methyl 4-amino-3-methoxybenzoate(41608-64-4)

Safety Data

• Hazard Codes: Xi,Xn
• Statements: 22
• HazardClass: IRRITANT
• Hazardous Substances Data: 41608-64-4(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
Methyl 4-amino-3-methoxybenzoate is used as an intermediate in the synthesis of various pharmaceuticals and organic compounds. Its role in the production of these compounds is crucial, as it contributes to the development of new medications and therapeutic agents.
Used in Cosmetic Products:
In the cosmetic industry, Methyl 4-amino-3-methoxybenzoate is used as a flavoring agent and fragrance ingredient. Its slightly sweet odor makes it a valuable addition to the formulation of various cosmetic products, enhancing their sensory appeal.
Safety Considerations:
It is important to handle Methyl 4-amino-3-methoxybenzoate with care, as it may cause irritation to the skin, eyes, and respiratory system. Proper safety measures should be taken during its production, use, and disposal to minimize potential health risks.

InChI:InChI=1/C9H11NO3/c1-12-8-5-6(9(11)13-2)3-4-7(8)10/h3-5H,10H2,1-2H3

Upstream product

• 38512-82-2 3-methoxy-4-nitrotoluene 
• 713-52-0 methyl 3-hydroxy-4-nitrobenzoate 
• 5368-81-0 methyl 3-methoxybenzoate 
• 67-56-1 methanol 
• 2486-69-3 3-methoxy-4-aminobenzoic acid 
• 5081-37-8 methyl 3-methoxy-4-nitrobenzoate 
• 619-14-7 3-hydroxy-4-nitro-benzoic acid 
• 5081-36-7 3-methoxy-4-nitrobenzoic acid 

Downstream Products

• 208399-31-9 N,N',N''-(nitrilotri-2,1-ethanediyl)tris(2,2'-dihydroxy-4-biphenylcarboxamide) 
• 208399-30-8 N,N',N''-(nitrilotri-2,1-ethanediyl)tris(2,2'-dimethoxy-4-biphenylcarboxamide) 
• 74385-19-6 2-(4-Fluoro-3-methoxy-phenyl)-propan-2-ol 
• 74385-34-5 2,3-bis(4'-fluoro-3'-hydroxyphenyl)-2,3-dimethylbutane 
• 74385-26-5 2,3-bis(4'-fluoro-3'-methoxyphenyl)-2,3-dimethylbutane 
• 1069130-69-3 3-formyl-6-hydroxy-1-methoxy-9H-carbazole 
• 1356588-31-2 C₂₅H₂₃N₅O₃ 
• 1419186-29-0 4-{[(2'S,3'R,4'S,5'R)-6-chloro-4'-(3-chloro-2-fluorophenyl)-2'-(2,2-dimethylpropyl)-2-oxo-1,2-dihydrospiro[indole-3,3'-pyrrolidine]-5'-carbonyl]amino}-3-methoxybenzoic acid dimethyl-((R)-1-phenylethyl)amine salt 
• 1309684-94-3 (2'S,3'R,4'S,5'R)-6-chloro-4'-(3-chloro-2-fluorophenyl)-2'-(2,2-dimethylpropyl)-2-oxo-1,2-dihydrospiro[indole-3,3'-pyrrolidine]-5'-carboxylic acid (4-carbamoyl-2-methoxyphenyl)amide 
• 1345866-83-2 4-{2-[3,3-dimethyl-but-(E)-ylideneamino]acetylamino}-3-methoxybenzoic acid methyl ester 
• 247035-42-3 methyl 4-(4-hydroxypiperidin-1-yl)-3-methoxybenzoate 
• 247035-44-5 methyl 4-{4-(methanesulfonyloxy)piperidin-1-yl}-3-methoxybenzoate 
• 247035-43-4 4-(4-azido-piperidin-1-yl)-3-methoxy-benzoic acid methyl ester 
• 568584-57-6 methyl 4-(4-aminopiperidin-1-yl)-3-methoxybenzoate 

Relevant articles and documents

Total synthesis of inubosin B

Inubosin B is the most active member of the acridine alkaloids isolated from Streptomyces sp. IFM 11440 culture. The inubosins initiate neuroregeneration via a neurogenine 2 pathway. In this work, we have described the total synthesis of inubosin B via two synthetic routes. The effects of various coupling, cyclization and reduction reactions are discussed including common pitfalls and side reactions. Reverse phase chromatography with TFA was crucial for the isolation of the product from aluminum ions present in the reduction media.

AZAINDOLE DERIVATIVE AND USE THEREOF AS FGFR AND C-MET INHIBITOR

A series of pyrazolopymidine derivatives, and use thereof in the preparation of a medicament for treating disease associated with FGFR and c-Met. The pyrazolopymidine derivative is a compound represented by formula (I), a tautomer, or a pharmaceutically acceptable salt thereof.

NEW CLASS OF DNA GYRASE AND/OR TOPOISOMERASE IV INHIBITORS WITH ACTIVITY AGAINST GRAM-POSITIVE AND GRAM-NEGATIVE BACTERIA

The present invention relates to compounds having a structure of general formula (I), processes for their preparation, pharmaceutical compositions containing them as the active ingredient, to their use as medicaments and to their use in the manufacture of medicaments for use in the treatment of bacterial infections in humans and warm-blooded animals.

SPIROCYCLIC INDOLONE POLYETHYLENE GLYCOL CARBONATE COMPOUND, COMPOSITION, PREPARATION METHOD AND USE THEREOF

The present invention relates to a spirocyclic indolone polyethylene glycol carbonate compound, a composition thereof, a preparation method therefor, and a use thereof as an anticancer drug due to the antitumor activity thereof. The structural formula of the spirocyclic indolone polyethylene glycol carbonate compound is shown below. The compound has excellent tumor inhibitory activity, water solubility, low toxicity, and can be used for intravenous injection.

Spiroindolone polyethylene glycol carbonate compound, and compositions, preparation method and application thereof

The invention relates to a spiroindolone polyethylene glycol carbonate compound, compositions and a preparation method thereof, and an application of the spiroindolone polyethylene glycol carbonate compound as an anticancer drug due to antitumor activity of the spiroindolone polyethylene glycol carbonate compound. The spiroindolone polyethylene glycol carbonate compound has a structural formula asdescribed in the specification, has excellent tumor suppressive activity, good water solubility and low toxicity, and can be used for intravenous injections.

Acylhydrazone compounds with anti-tumor activity as well as preparation method and application of acylhydrazone compounds

The invention belongs to the technical field of medicinal chemistry, and in particular relates to acylhydrazone compounds with anti-tumor activity as well as a preparation method and application of the acylhydrazone compounds. The structures of the acylhydrazone compounds are as shown in a general formula (I) shown in the description, wherein R and R' are independently selected from any one or more of halogen, amino, cyano, alkoxy, 3,4-methylenedioxy, nitro, phenyl or substituted phenyl, and R and R' substituents are mono-substituted, disubstituted or tri-substituted. The preparation method issimple; biological activity test results of the compounds show that the compounds have a very good inhibitory effect on histone methyltransferase SET7, and have good application prospect in the development of anti-tumor aspects.

Synthesis of the γ-Secretase Modulator MK-8428

The synthesis of the γ-secretase modulator MK-8428 (1) is described. The synthesis is highlighted by an enzyme-catalyzed reaction to access 3,4,5-trifluoro-(S)-phenylglycine, a 1-pot activation/displacement/deprotection sequence to introduce the aminooxy functionality and a dehydrative intramolecular cyclization under mild conditions to form the oxadiazine heterocycle of 1. In situ reaction monitoring was employed to understand the deleterious role of water during the formation of a methanesulfonate ester in the 1-pot activation/displacement/deprotection sequence.

CYSTOBACTAMIDES

The present invention provides cystobactamides of formula (I) and the use thereof for the treatment or prophylaxis of bacterial infections:

Synthesis and biological evaluation of cystobactamid 507: A bacterial topoisomerase inhibitor from Cystobacter sp.

Abstract The first total synthesis of cystobactamid 507, a member of a class of new natural products with strong inhibitory activity towards bacterial topoisomerases, is reported. Synthetic key challenges are the central tetrasubstitued arene and the low chemical reactivity of anilines and ortho-phenolic and isopropoxy-substituted benzoic acids. Biological evaluations demonstrate that cystobactamid 507 inhibits several Gram-positive pathogens but at significantly lower concentrations than described for the larger members of this natural product family.

BENZAMIDE DERIVATIVE

The present invention relates to benzamide derivatives represented by formula (I) or pharmaceutically acceptable salts thereof.